aBSI
AI-driven automated bone scan analysis for medical imaging
Software · OtherCompany source
Company profile
About EXINI Diagnostics
EXINI Diagnostics AB is a medical imaging AI company that develops advanced automated analysis platforms for nuclear medicine and radiology. Founded in 1999 as a spinout from Lund University research, the company has over 25 years of experience commercializing AI-driven methods for automated medical image analysis. EXINI's product portfolio includes aBSI for bone imaging, aPROMISE for prostate cancer PSMA analysis, CURE8 for brain imaging, and PYLCLARI AI for amyloid imaging. These certified solutions provide quantifiable and reproducible assessments that enable precision oncology and improved diagnostic workflows. The company's technology is trusted by over 800 clinical sites worldwide and focuses on key clinical areas including PSMA imaging for prostate cancer, brain imaging, and bone scan analysis. EXINI serves healthcare providers, pharmaceutical companies, and research institutions with both clinical software and pharma services. The company is headquartered in Lund, Sweden at the Ideon Science Park and operates as a wholly owned subsidiary of Lantheus Holdings, Inc., a publicly traded medical imaging company.
Company description EXINI Diagnostics official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at EXINI Diagnostics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Amyloid imaging conditions
- Bone metastases
- Brain disorders
- Prostate cancer
Who it serves
- Healthcare providers
- Nuclear medicine departments
- Pharmaceutical companies
- Research institutions
Deployment & integration
Other deployment with recorded integration context.
Recorded integration context: Siemens Healthineers syngo.via.
Geographic context
MarketsCanada · European Union · Global - 800+ sites worldwide · Sweden · USA
Company sourceOfficial website
Company milestones
Platform expansion
Joined EU's Thera4Care Project (October 2024); Released new version of aPROMISE with semi-automatic hotspot drawing and viewport layout features (August 2024); Integrated aPROMISE solution on Siemens Healthineers syngo.via platform demonstrated at SNMMI annual meeting (June 2024)
Partnerships
Recorded partners
- EU Thera4Care consortium
- Lantheus Holdings, Inc. (parent company)
- Siemens Healthineers
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
aPROMISE
AI-enabled PSMA analysis platform for prostate cancer imaging
Software · OtherCompany source
CURE8
AI-powered medical imaging analysis solution
Software · OtherCompany source
PYLCLARI AI
AI-driven brain imaging analysis platform
Software · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Early detection and localization of recurrent prostate cancer using [Formula: see text]F-DCFPyL PET/CT in patients with low and ultra-low PSA levels.EJNMMI research · Jul 27, 2026
Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.Annals of nuclear medicine · Jun 9, 2026
Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · Feb 4, 2026
Deep learning models built from PSMA PET of the primary tumor can predict synchronous and metachronous prostate cancer metastases.PloS one · Jan 1, 2026
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.The Prostate · Sep 1, 2022
Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting.European journal of nuclear medicine and molecular imaging · Feb 1, 2022
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Quantifiable and reproducible PSMA uptake assessment
Enables precision oncology in prostate cancer
Standardization of PSMA scan reports
Enhances reproducibility and timeliness of scan interpretations
Automated quantification of molecular expression
Individual tumor lesion detection and quantification
Duke University
Providing quantifiable and reproducible assessment of PSMA uptake and distribution for precision oncology in prostate cancer
Enabled precision oncology in prostate cancer through standardized PSMA assessment
Jewish General Hospital Montreal
Implementation of PSMA-AI for diagnostic imaging advancement
Step towards AI-powered diagnostic imaging that can match human expert performance
Memorial Sloan Kettering Cancer Center
Advancing molecular imaging in cancer detection and quantification of molecular expression in prostate cancer
Enhanced capability to detect and quantitate molecular expression of individual tumor lesions
UCLA David Geffen School of Medicine
Quantification and standardization of PSMA scan reports to enhance reproducibility and timeliness
Major step forward in reproducibility and timeliness of scan interpretations
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Aseem
Vice President
Karl
Data Science
Fredrik
Business Development
Jens
Site Manager and Machine Learning
Mike
Device Development
06 · Company updates
Updates from EXINI Diagnostics
Recent articles published on EXINI Diagnostics's official website.
EXINI Executes Agreement with Bayer AG for the Distribution of its PSMA Artificial Intelligence Technology aPROMISE and quantitative assessment technology of bone scans aBSI
Read on EXINI DiagnosticsEXINI executes agreement with INmune Bio for Phase I/II trial
Read on EXINI DiagnosticsLantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI® at the 2023 EuropeanAssociation of Nuclear Medicine (EANM) Annual Meeting
Read on EXINI DiagnosticsEXINI Diagnostics AB, a Lantheus company (EXINI), announced today a ‘License and Development’ agreement with Curium, a world leader in nuclear medicine , to customize EXINI’s artificial intelligence (AI) platform for use in Europe.
Read on EXINI DiagnosticsNew version released of PYLARIFY AI® (aPROMISE)
Read on EXINI Diagnostics07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.